Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
Recruiting · NCT05424159 · Interventional (participants receive a specific treatment) · Lead sponsor: Shanghai Proton and Heavy Ion Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultaneous integrated boost (SIB) technology.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Have the ability to sign the written informed consent;
- Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;
- Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);
- The maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;
- Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);
- Eastern Cooperative Oncology Group (ECOG) performance score 0-1;
- Adequate bone marrow function (neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10.0g/dL);
- Adequate liver function (total bilirubin \<1.5 times the upper limit of normal value, aminotransferase \<2.5 times the upper limit of normal value);
- Adequate renal function (serum creatinine \<2mg/dL, or creatinine clearance \>50mL/min).
Exclusion criteria
- Multiple primary pancreatic lesions (\>1);
- Tumor invaded the adjacent digestive tract;
- Radiation therapy history;
- Other local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;
- The irradiation dose of organs at risk cannot reach the dose constraint;
- Other malignant tumors history;
- Inability to understand the purpose of treatment or unwillingness/inability to sign informed consent.
Where it is running
1 location listed.
- Shanghai Proton and Heavy Ion Center - Shanghai, China